All questions
Clinical trials: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults
5 questions · 3 sources
Clinical trials questions that apply to every indication of Prevnar 20 are on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Clinical trials.
Interpreting study results
How was Prevnar 20 effectiveness in adults established?
Study results
Prevnar 20 vs Prevnar 13 and PPSV23: how did immune responses compare in adults 60+?
Applies to Pneumococcal vaccine-naive adults 60 years of age and older (Study 1)
Note: Study 1 compared Prevnar 20 with Prevnar 13 for the 13 shared serotypes and with PPSV23 (23-valent pneumococcal polysaccharide vaccine) for the 7 additional serotypes. The label reports each serotype's GMTs and GMT ratio in Table 13.
How was Prevnar 20 effectiveness inferred in adults 18 to 59?
Applies to Pneumococcal vaccine-naive adults 18 through 59 years of age (Study 1 immunobridging)
What immune responses did Prevnar 20 produce in previously vaccinated adults 65+?
Applies to Adults 65 years of age and older previously vaccinated with a pneumococcal vaccine (Study 6)
What did the Prevnar 13 CAPiTA trial show in adults 65 and older?
Applies to Prevnar 13 (13-valent predecessor vaccine) in adults 65 years of age and older (CAPiTA); cited by the label as relevant to Prevnar 20
Note: CAPiTA tested Prevnar 13, the 13-valent predecessor vaccine. In Table 8, the episode columns are the total, Prevnar 13 (n), and placebo (N), followed by vaccine efficacy (VE) with its 95.2% CI.